BDBM330053 (2R,5S,13aR)-N-(2-chloro-4-fluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][3]oxazepine-10-carboxamide::US9663528, 63
SMILES: Oc1c2C(=O)N3[C@H]4CC[C@H](C4)[C@H]3Cn2cc(C(=O)NCc2ccc(Cl)cc2F)c1=O
InChI Key: InChIKey=CLDKIKVUKMVPFT-AKWBHNSASA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solute carrier family 22 member 2 (Homo sapiens (Human)) | BDBM330053 ((2R,5S,13aR)-N-(2-chloro-4-fluorobenzyl)-8-hydroxy...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 42 | n/a | n/a | n/a | n/a | n/a | n/a |
Gilead Sciences, Inc. US Patent | Assay Description The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an... | US Patent US9663528 (2017) BindingDB Entry DOI: 10.7270/Q24F1SVF | |||||||||||
More data for this Ligand-Target Pair |